Patent applications published 5 January 2011

Published: 2-Feb-2011

Selected patent applications from the weekly European Patents Bulletin


  • Novel compounds advantageous in the treatment of central nervous system diseases and disorders
    Aurimmed Pharma 2268140*

  • Compounds and methods for reducing uric acid
    Wellstat Therapeutics 2268141*

  • Use of alginated oligomers in combating biofilms
    Algipharma 2268142*

  • Novel piperidine derivatives as inhibitors of stearoyl-CoA desaturase
    Forest Laboratories Holdings 2268143*

  • Indolene anti-cancer agents
    Joyant Pharmaceuticals 2268146*

  • Mixture of peptide-bound tryptophan and polypeptide-bound tryptophan
    DSM IP 2268157*

  • Cross-linked polymer matrix, in particular for administering active ingredients
    Universität Regensberg 2268264*

  • Compsns for site-specific delivery of Imatinib and methods of use
    Elan Pharma International 2268265*

  • Process for obtaining powder compsns of Orlistat to be filled into a capsule
    Zaklady Faramceutyczne ‘Polpharma’ 2268266*

  • Dry transglutaminase compsn
    Novo Nordisk 2268267*

  • Orally disintegrating compsns of rhein or diacerein
    Wockhardt Research Centre 2268268*

  • Sulfoalkyl ether cyclodextrin compsns
    CyDex Pharmaceuticals 2268269*

  • Improved formulations for poorly permeable active pharmaceutical ingredients
    Abbott Products 2268270*

  • Hand sanitising patch
    Lectec 2268271*

  • Compounds that modulate negative-sense, single-stranded RNA virus replication and uses thereof
    Mount Sinai School of Medicine of New York University 2268272*

  • Small-molecule modulators of TRP0P8 activity
    Dendreon 2268273*

  • Vitamin E derivatives and their uses
    Virun 2268274*

  • Antimicrobials having polyquarternary ammoniums and alcohol-bearing amidoamines and methods for their use
    Abbott Medical Optics 2268275*

  • Compsns for the treatment and prevention of infections of the oral cavity
    Indena 2268276*

  • Use of flavonoide compounds for the prophylaxis and therapy of ischaemic or inflammatory cardiovascular diseases
    Boehringer Ingelheim International 2268277*

  • Pharmaceutical compsn
    Shorr, Robert 2268278*

  • Treatment of psoriasis or psoriatic arthritis using cyclopropyl-N-{2-[(1S)-1-(3- ethoxy-4-methoxyphenyl)-2-methylsulphonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
    Celgene 2268279*

  • Quinolizidinone M1 receptor positive allosteric modulators
    Merck Sharp & Dohme 2268280*

  • Thienopyrroles and pyrrolothiazoles as new therapeutic agents
    Abbott Laboratories 2268281*

  • Liquid formulation for deferiprone with palatable taste
    Apotex Technologies 2268282*

  • Oral modified-release formulations containing thiazepines
    Dexcel 2268283*

  • Use of G-rich oligonucleotides for treating neoplastic diseases
    Antisoma Research 2268284*

  • Therapeutic compounds
    Merck Sharp & Dohme 2268285*

  • Methods of regulating actin cytoskeletal rearrangement and intercellular gap formulation
    The University of North Carolina at Chapel Hill 2268286*

  • Method of administering antitumour agent comprising deoxycytidine derivative
    Taiho Pharmaceutical; Sasaki, Takuma; Matsuda, Akira 2268287*

  • Nucleoside derivatives for treatment of calciviridae infections, including norovirus infections
    RFS Pharma; Emory University 2268288*

  • Anti-infective agents and uses thereof
    Innate Therapeutics 2268289*

  • Styrene maleic anhydride based formulation for male contraception and prostate cancer
    Guha, Sujoy Kumar 2268290*

  • Treatment for the hair regrowth in the bald patches formed by alopecia of the celsi area
    Aliotta, Rocco; Aliotto, Nicola 2268291*

  • Method and compsns for treatment of cancer
    Kornipharm International 2268292*

  • Stem cell compsn for inducing transplant tolerance
    Smt G R Doshi and Smt K M Mehta Institute of Kidney Diseases and Research Centre 2268293*

  • Propolis extract
    Gehrlicher Pharmazeutische Extrakte 2268294*

  • Activation of innate and adaptive immune responses by a ginseng extract
    Afexa Life Sciences 2268295*

  • Compsns and method for the diagnosis, prevention and treatment of Alzheimer’s disease
    SNU R&DB Foundation 2268296*

  • Modified toxins
    Angelica Therapeutics 2268297*

  • Novel GP96 derived peptides
    Compugen 2268298*

  • Compsns and method for reducing scar formation in wound healing
    MosaMedix 2268299*

  • Methods for the inhibition of scarring
    Renovo 2268300*

  • Erythropoietin and fibronectin compsns for bone regeneration
    Remedor Biomed 2268301*

  • BMP-7 for use in treating vascular sclerosis
    Hruska, Keith; Choi, Eric 2268302*

  • Novel uses of VEG xxxB
    The University of Bristol 2268303*

  • Methods for treating acute myocardial infarction
    Orthologic 2268304*

  • Oxidised paraoxanase 1 and araoxonade 1/HDL particle number ratio as risk markers for cardiovascular disease
    The Cleveland Clinic Foundation 2268305*

  • Therapeutic cancer antigens
    The Board of Trustees of the University of Illinois 2268306*

  • Vaccine
    GlaxoSmithKline Biologicals 2268307*

  • Vaccine for protection against Lawsonia intracellulars
    Intervet International 2268308*

  • Improvements in preparation of influenza virus vaccine antigens
    Novartis 2268309*

  • Use of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-Hodgkin’s lymphomas
    Roche Glycart 2268310*

  • Non-invasive systems and methods for in-situ photobiomodulation
    Immunolight; Duke University 2268311*

  • Treatment of intervertebral disc degeneration
    Tissuegene 2268312*

  • YOPM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
    Universitätsklinikum Münster 2268313*

  • Use of pyrene to carry peptides across the blood brain barrier
    Adlyfe 2268314*

  • Drug conjugates with polyglycerols
    Freie Universität Berlin; KTP Tumorforschungsgesellschaft 2268315*

  • Novel siRNA compounds for inhibiting RTP801
    Quark Pharmaceuticals 2268316*

  • Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
    Visen Medical; Merck Sharp & Dohme 2268317*

  • A tumour model system to study multi-stage cancer
    Council of Scientific and Industrial Research, India 2268318*

  • Precursors of lipid metabolism for the diagnosis and treatment of cancer
    Universität Ulm 2268319*

  • Image-guided therapy of myocardial disease: compsn, manufacturing and applications
    The Board of Regents of the University of Texas System 2268320*

  • Method of determining alanine transaminase (ALT) activity by 13C-MR detection using hyperpolarised 13-C pyruvate
    General Electric; The Regents of the University of California 2268321*

  • Interaction control of cationic biocides using labile anionic polyelectrolytes
    Alcon Research 2268322*

  • Fibrin foam and process
    Baxter International 2268323*

  • Fibrin foam and process for making
    Baxter International 2268324*

  • Bioresorbable material
    Gottfried Wilhelm Leibniz Universität Hannover 2268325*

  • Substituted 1,3-cyclopentadione attenuated endothelial-monocyte interactions
    Metaproteomics 2268600*

  • Method for preparing difluoroacetic acid and salts thereof
    Rhodia Opérations 2268601*

  • Method for producing diamonodiphenyl alkanes
    Evonik Degussa 2268602*

  • Process for the preparation of 2-amino-2-[2-(4-C3-C21-alkyl-phenyl)ethyl]propane-1,3-diols
    Novartis 2269603*

  • Therapies for cancer using isotopically substituted lysine
    Retrotope 2268604*

  • Fatty acid derivatives for oral administration endowed with high palatability
    Berni Canani, Roberto; Calignano, Antonio; Mazzoni, Orietta; Coruzzo, Anna 2168605*

  • 4-dimethylaminobutyric acid derivatives
    F Hoffmann-La Roche 2268606*

  • Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid
    Cti Bio 2268607*

  • Stabilised nucleic acid dark quencher-fluorophore probes
    Biosearch Technologies 2268608*

  • Synthesis of a PEG-6 moiety from commercial low-cost chemicals
    GE Healthcare 2268609*

  • Aminoalkylphenyl antagonists of prostaglandin D2 receptors
    Amira Pharmaceuticals 2268611*

  • Arylsulphonamide-based matrix metalloprotease inhibitors
    Novartis 2268612*

  • Inhibitors of cell proliferation and uses thereof
    European Molecular Biology Laboratory 2268613*

  • Method for producing beta-mercapto carboxylic acids
    Showa Denko 2268614*

  • Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
    Chlorion Pharma 2268616*

  • Process for the resolution of isoquinoline derivatives
    Recordati Industria Chimica E Farmaceutica 2268617*

  • Compounds and compsns as TLR activity modulators
    IRM LLC 2268618*

  • Fluorinated macrocyclic compounds as hepatitis C virus inhibitors
    Enanta Pharmaceuticals 2268619*

  • Inhibitors of antigen receptor-induced NF-kappa B activation
    Burnham Institute for Medical Research; Human Biomolecular Research Institute 2268620*

  • Regioselective preparation of substituted pyrimidines
    Boehringer Ingelheim International 2268621*

  • Regioselective preparation of substituted pyrimidines
    Boehringer Ingelheim International 2268622*

  • Quinazoline derivatives as RAF kinase modulators and methods of use thereof
    Ambit Biosciences 2268623*

  • Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
    Merck Patent 2268624*

  • Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof
    Bayer Schering Pharma 2268625*

  • 5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of HSP90 chaperone and the intermediates for production thereof
    Biotechnologijos Institutas 2268626*

  • 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain
    Rottapharm 2268628*

  • Photochromic naphthopyranes having a double-bridged terphenyl sub-unit
    Rodenstock 2268629*

  • Hexahydrocyclopentyl[F]indazole carboxamides and derivatives thereof as selective glucocorticoid receptor modulators
    Merck Sharp & Dohme 2268630*

  • Aminopiperidinyl derivatives and uses thereof
    F Hoffmann-La Roche 2268631*

  • Tertiary amine derivatives as phosphodiesterase-4 inhibitors
    Chiesi Farmaceutici 2268632*

  • Pyrazinone glucokinase activators
    F Hoffmann-La Roche 2268633*

  • Processes for the preparation of bosentan and related compounds using novel intermediates
    Actavis Group 2268634*

  • Heterocyclic compounds
    Taigen Biotechnology 2268635*

  • Gamma secretase modulators
    Schering 2268636*

  • Traizolopyridineone derivatives for use as stearoyl CoA desaturase inhibitors
    Gilead Sciences 2268637*

  • Tetrahydronaphthyridines and aza derivatives thereof as histamine H3 receptor antagonists
    Evotec 2268638*

  • Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
    Teva Pharmaceuticals Industries 2268639*

  • Process for preparing enantiomerically pure indolopyridines
    4SC 2268640*

  • Heterocyclic compounds as adenosine receptor antagonist
    Advinus Therapeutics 2268641*

  • 1’-substituted carba-nucleoside analogues for antiviral treatment
    Gilead Sciences 2268642*

  • Dioxalane and dioxolanone fused indolobenxadiazepine HCV NS5B inhibitors
    Bristol-Myers Squibb 2268643*

  • Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
    Boehringer Ingelheim International 2268644*

  • Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidines, preparation and use thereof as allosteric modulators of MGLUR
    Sanofi-Aventis 2268645*

  • Thiazolopyridin-2-yloxy-phenyl and thiazolopyridin-2-yloxy-phenylamines as modulators of leukotriene A4 hydrolase
    Janssen Pharmaceutica 2268646*

  • Compounds and compsns for the detection and treatment of Alzheimer’s disease and related disorders
    The General Hospital Corp 2268647*

  • Crystalline (6R,7R)-7-(2-(5-amino-[1,2,4]-thiadiazol-3-yl)-2-[(Z)-trityloxyimino-acetylamino]-3-[(R)-1’-tert-butoxycarbonyl-2-oxo-[1,3]-bipyrrolidinyl-(3E)-ylidone-methyl]-8-oxo-5-thia-1-aza-bicyclo[4,2,0]oct-2-ene-2-carboxylic acid benzhydryl ester, its manufacture and use
    Basilea Pharmaceutica 2268648*

Trending Articles

You may also like